

# Manuel Hidalgo

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4198699/publications.pdf>

Version: 2024-02-01

241  
papers

40,524  
citations

6124

83  
h-index

2823

197  
g-index

247  
all docs

247  
docs citations

247  
times ranked

46208  
citing authors

#	ARTICLE	IF	CITATIONS
1	Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 708-718.	3.2	38
2	Saliva-Based, COVID-19 RT-PCR Pooled Screening Strategy to Keep Schools Open. <i>Disaster Medicine and Public Health Preparedness</i> , 2022, , 1-6.	0.7	4
3	Trybeca-1: A randomized, phase 3 study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with advanced pancreatic adenocarcinoma (NCT03665441).. <i>Journal of Clinical Oncology</i> , 2022, 40, 518-518.	0.8	10
4	American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review of evidence. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 827-854.e3.	0.5	12
5	SOX9 Triggers Different Epithelial to Mesenchymal Transition States to Promote Pancreatic Cancer Progression. <i>Cancers</i> , 2022, 14, 916.	1.7	6
6	ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations. <i>Gastrointestinal Endoscopy</i> , 2022, 95, 817-826.	0.5	31
7	Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC).. <i>Journal of Clinical Oncology</i> , 2022, 40, TPS4188-TPS4188.	0.8	3
8	Facts and Hopes in Immunotherapy of Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2022, 28, 4606-4617.	3.2	23
9	Is PD-L1 a consistent biomarker for anti-PD-1 therapy? The model of balstilimab in a virally-driven tumor. <i>Oncogene</i> , 2021, 40, 1393-1395.	2.6	53
10	Elevated levels of mitochondrial CoQ10 induce ROS-mediated apoptosis in pancreatic cancer. <i>Scientific Reports</i> , 2021, 11, 5749.	1.6	14
11	Reply to K. de Joode et al. <i>Journal of Clinical Oncology</i> , 2021, 39, 1093-1094.	0.8	0
12	Differentiated activity profile for the PD-1 inhibitor balstilimab.. <i>Journal of Clinical Oncology</i> , 2021, 39, 5529-5529.	0.8	2
13	Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Trial. <i>Clinical Cancer Research</i> , 2021, 27, 5020-5027.	3.2	37
14	A Grant-Based Experiment to Train Clinical Investigators: The AACR/ASCO Methods in Clinical Cancer Research Workshop. <i>Clinical Cancer Research</i> , 2021, 27, 5472-5481.	3.2	4
15	Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. <i>Cell</i> , 2021, 184, 4753-4771.e27.	13.5	99
16	Abstract PO-050: Precision Promise (PrP): An adaptive, multi-arm registration trial in metastatic pancreatic ductal adenocarcinoma (PDAC). <i>Cancer Research</i> , 2021, 81, PO-050-PO-050.	0.4	2
17	Empirical identification and validation of tumor-targeting T cell receptors from circulation using autologous pancreatic tumor organoids. , 2021, 9, e003213.		25
18	VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. , 2021, 9, e003254.		31

#	ARTICLE	IF	CITATIONS
19	From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. <i>Nature Reviews Clinical Oncology</i> , 2020, 17, 108-123.	12.5	244
20	Hematology and oncology clinical care during the coronavirus disease 2019 pandemic. <i>Ca-A Cancer Journal for Clinicians</i> , 2020, 70, 349-354.	157.7	18
21	Lewis Antigen Phenotype and Survival of Patients With Pancreatic Cancer. <i>Pancreas</i> , 2020, 49, 1348-1354.	0.5	6
22	Clinical Screening for COVID-19 in Asymptomatic Patients With Cancer. <i>JAMA Network Open</i> , 2020, 3, e2023121.	2.8	20
23	CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. <i>Cancer Cell</i> , 2020, 37, 340-353.e6.	7.7	114
24	BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. <i>Nature Medicine</i> , 2020, 26, 878-885.	15.2	297
25	PDX-derived organoids model in vivo drug response and secrete biomarkers. <i>JCI Insight</i> , 2020, 5, .	2.3	66
26	COVID-19 Severity and Outcomes in Patients With Cancer: A Matched Cohort Study. <i>Journal of Clinical Oncology</i> , 2020, 38, 3914-3924.	0.8	111
27	Phase II trial of BPM31510-IV plus gemcitabine in advanced pancreatic ductal adenocarcinomas (PDAC).. <i>Journal of Clinical Oncology</i> , 2020, 38, 723-723.	0.8	3
28	TRYbeCA-1: A randomized, phase III study of eryaspase in combination with chemotherapy versus chemotherapy alone as second-line treatment in patients with pancreatic adenocarcinoma (NCT03665441).. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4666-TPS4666.	0.8	0
29	Complete Regression of Advanced Pancreatic Ductal Adenocarcinomas upon Combined Inhibition of EGFR and C-RAF. <i>Cancer Cell</i> , 2019, 35, 573-587.e6.	7.7	75
30	Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cancer and an ECOG Performance Status of 2. <i>Journal of Clinical Oncology</i> , 2019, 37, 230-238.	0.8	66
31	Targeting protein disulfide isomerase with the flavonoid isoquercetin to improve hypercoagulability in advanced cancer. <i>JCI Insight</i> , 2019, 4, .	2.3	110
32	Personalized RNA Medicine for Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2018, 24, 1734-1747.	3.2	67
33	Exome Sequencing of Plasma DNA Portrays the Mutation Landscape of Colorectal Cancer and Discovers Mutated VEGFR2 Receptors as Modulators of Antiangiogenic Therapies. <i>Clinical Cancer Research</i> , 2018, 24, 3550-3559.	3.2	32
34	A Tricin Derivative from <i>Deschampsia antarctica</i> Desv. Inhibits Colorectal Carcinoma Growth and Liver Metastasis through the Induction of a Specific Immune Response. <i>Molecular Cancer Therapeutics</i> , 2018, 17, 966-976.	1.9	21
35	MT1-MMP as a PET Imaging Biomarker for Pancreas Cancer Management. <i>Contrast Media and Molecular Imaging</i> , 2018, 2018, 1-13.	0.4	13
36	Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. <i>International Journal of Cancer</i> , 2018, 143, 2053-2064.	2.3	76

#	ARTICLE	IF	CITATIONS
37	From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. <i>Journal of Cancer</i> , 2018, 9, 1978-1988.	1.2	27
38	More than a Gel & Hyaluronic Acid, a Central Component in the Microenvironment of Pancreatic Cancer. <i>European Oncology and Haematology</i> , 2018, 14, 40.	0.0	11
39	Interrogating open issues in cancer precision medicine with patient-derived xenografts. <i>Nature Reviews Cancer</i> , 2017, 17, 254-268.	12.8	527
40	Evaluation of BGI398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study. <i>Journal of Clinical Oncology</i> , 2017, 35, 157-165.	0.8	345
41	Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin. <i>Clinical Cancer Research</i> , 2017, 23, 5639-5647.	3.2	76
42	<i>GPX3</i> promoter methylation predicts platinum sensitivity in colorectal cancer. <i>Epigenetics</i> , 2017, 12, 540-550.	1.3	43
43	Pancreas Cancer Precision Treatment Using Avatar Mice from a Bioinformatics Perspective. <i>Public Health Genomics</i> , 2017, 20, 81-91.	0.6	10
44	A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. <i>Journal of Gastrointestinal Oncology</i> , 2017, 8, 925-935.	0.6	0
45	Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. <i>British Journal of Cancer</i> , 2016, 115, 442-453.	2.9	39
46	Phase II Trial of Target-guided Personalized Chemotherapy in First-line Metastatic Colorectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2016, 39, 236-242.	0.6	5
47	Combined inhibition of DDR1 and Notch signaling is a therapeutic strategy for KRAS-driven lung adenocarcinoma. <i>Nature Medicine</i> , 2016, 22, 270-277.	15.2	150
48	SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. <i>Molecular Cancer Therapeutics</i> , 2016, 15, 680-688.	1.9	49
49	Phase I Dose-Escalation Trial of the Oral Investigational Hedgehog Signaling Pathway Inhibitor TAK-441 in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 1002-1009.	3.2	39
50	Safety and Pharmacokinetics/Pharmacodynamics of the First-in-Class Dual Action HER3/EGFR Antibody MEHD7945A in Locally Advanced or Metastatic Epithelial Tumors. <i>Clinical Cancer Research</i> , 2015, 21, 2462-2470.	3.2	51
51	The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. <i>Gut</i> , 2015, 64, 1936-1948.	6.1	123
52	Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. <i>Clinical Cancer Research</i> , 2015, 21, 2325-2337.	3.2	170
53	SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial. <i>Clinical Cancer Research</i> , 2015, 21, 4811-4818.	3.2	117
54	Nivolumab and Urelumab Enhance Antitumor Activity of Human T Lymphocytes Engrafted in Rag2 <sup>−/−</sup> /IL2R <sup>β</sup> null Immunodeficient Mice. <i>Cancer Research</i> , 2015, 75, 3466-3478.	0.4	137

#	ARTICLE	IF	CITATIONS
55	Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. <i>Cancer Research</i> , 2015, 75, 3355-3364.	0.4	129
56	A first-in-human phase I trial of LY2780301, a dual p70 S6 kinase and Akt Inhibitor, in patients with advanced or metastatic cancer. <i>Investigational New Drugs</i> , 2015, 33, 710-719.	1.2	24
57	Examining the utility of patient-derived xenograft mouse models. <i>Nature Reviews Cancer</i> , 2015, 15, 311-316.	12.8	300
58	Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. <i>Gut</i> , 2015, 64, 1921-1935.	6.1	112
59	Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. <i>Nature Reviews Clinical Oncology</i> , 2015, 12, 319-334.	12.5	489
60	Vemurafenib in Multiple Nonmelanoma Cancers with <i>BRAF</i> V600 Mutations. <i>New England Journal of Medicine</i> , 2015, 373, 726-736.	13.9	1,483
61	Addressing the challenges of pancreatic cancer: Future directions for improving outcomes. <i>Pancreatology</i> , 2015, 15, 8-18.	0.5	404
62	Phase II randomized trial of MEK inhibitor pimasertib or placebo combined with gemcitabine in the first-line treatment of metastatic pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2015, 33, 344-344.	0.8	13
63	Whole Exome Sequencing of Rapid Autopsy Tumors and Xenograft Models Reveals Possible Driver Mutations Underlying Tumor Progression. <i>PLoS ONE</i> , 2015, 10, e0142631.	1.1	28
64	Pharmacogenomic Modeling of Circulating Tumor and Invasive Cells for Prediction of Chemotherapy Response and Resistance in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2014, 20, 5281-5289.	3.2	49
65	Metabolomic evaluation of Mitomycin C and rapamycin in a personalized treatment of pancreatic cancer. <i>Pharmacology Research and Perspectives</i> , 2014, 2, e00067.	1.1	14
66	A Prospective Pilot Study of Target-guided Personalized Chemotherapy with Intensity-modulated Radiotherapy in Patients With Early Rectal Cancer. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 2014, 37, 117-121.	0.6	23
67	Phase I study of carboplatin in combination with PM00104 (Zalypsis®) in patients with advanced solid tumors. <i>Investigational New Drugs</i> , 2014, 32, 644-652.	1.2	1
68	Colorectal cancer classification based on gene expression is not associated with FOLFIRI response. <i>Nature Medicine</i> , 2014, 20, 1230-1231.	15.2	8
69	Patient-Derived Xenograft Models: An Emerging Platform for Translational Cancer Research. <i>Cancer Discovery</i> , 2014, 4, 998-1013.	7.7	1,341
70	Intracellular autofluorescence: a biomarker for epithelial cancer stem cells. <i>Nature Methods</i> , 2014, 11, 1161-1169.	9.0	170
71	Transcriptional dissection of pancreatic tumors engrafted in mice. <i>Genome Medicine</i> , 2014, 6, 27.	3.6	41
72	Integrated Next-Generation Sequencing and Avatar Mouse Models for Personalized Cancer Treatment. <i>Clinical Cancer Research</i> , 2014, 20, 2476-2484.	3.2	140

#	ARTICLE	IF	CITATIONS
73	Chloroquine Targets Pancreatic Cancer Stem Cells via Inhibition of CXCR4 and Hedgehog Signaling. <i>Molecular Cancer Therapeutics</i> , 2014, 13, 1758-1771.	1.9	135
74	Molecular effects of lapatinib in patients with HER2 positive ductal carcinoma in situ. <i>Breast Cancer Research</i> , 2014, 16, R76.	2.2	14
75	Accurate Identification of ALK Positive Lung Carcinoma Patients: Novel FDA-Cleared Automated Fluorescence In Situ Hybridization Scanning System and Ultrasensitive Immunohistochemistry. <i>PLoS ONE</i> , 2014, 9, e107200.	1.1	58
76	Level of <i>HER2</i> Gene Amplification Predicts Response and Overall Survival in HER2-Positive Advanced Gastric Cancer Treated With Trastuzumab. <i>Journal of Clinical Oncology</i> , 2013, 31, 4445-4452.	0.8	170
77	Increased Survival in Pancreatic Cancer with nab-Paclitaxel plus Gemcitabine. <i>New England Journal of Medicine</i> , 2013, 369, 1691-1703.	13.9	5,097
78	The ALK translocation in advanced non-small-cell lung carcinomas: preapproval testing experience at a single cancer centre. <i>Histopathology</i> , 2013, 62, 609-616.	1.6	16
79	Phase 2 Study of Erlotinib Combined With Adjuvant Chemoradiation and Chemotherapy in Patients With Resectable Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 86, 678-685.	0.4	35
80	Correlation of Smad4 Status With Outcomes in Patients Receiving Erlotinib Combined With Adjuvant Chemoradiation and Chemotherapy After Resection for Pancreatic Adenocarcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2013, 87, 458-459.	0.4	21
81	Notch signaling pathway targeted therapy suppresses tumor progression and metastatic spread in pancreatic cancer. <i>Cancer Letters</i> , 2013, 335, 41-51.	3.2	125
82	Primary Human Non-small Cell Lung and Pancreatic Tumorgraft Models—Utility and Applications in Drug Discovery and Tumor Biology. <i>Current Protocols in Pharmacology</i> , 2013, 61, Unit 14.26.	4.0	21
83	Phase I pharmacokinetic and pharmacodynamic study of cetuximab, irinotecan and sorafenib in advanced colorectal cancer. <i>Investigational New Drugs</i> , 2013, 31, 345-354.	1.2	17
84	The Winning Formulation: The Development of Paclitaxel in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2013, 19, 5572-5579.	3.2	56
85	Personalized Chemotherapy Profiling Using Cancer Cell Lines from Selectable Mice. <i>Clinical Cancer Research</i> , 2013, 19, 1139-1146.	3.2	24
86	Metformin Targets the Metabolic Achilles Heel of Human Pancreatic Cancer Stem Cells. <i>PLoS ONE</i> , 2013, 8, e76518.	1.1	147
87	Tyrosine Phosphorylation Modulates the Vascular Responses of Mesenteric Arteries from Human Colorectal Tumors. <i>BioMed Research International</i> , 2013, 2013, 1-8.	0.9	2
88	The Relative Expression of Mig6 and EGFR Is Associated with Resistance to EGFR Kinase Inhibitors. <i>PLoS ONE</i> , 2013, 8, e68966.	1.1	31
89	Multimodal Treatment Eliminates Cancer Stem Cells and Leads to Long-Term Survival in Primary Human Pancreatic Cancer Tissue Xenografts. <i>PLoS ONE</i> , 2013, 8, e66371.	1.1	33
90	HER2/neu testing for anti-HER2-based therapies in patients with unresectable and/or metastatic gastric cancer. <i>Journal of Clinical Pathology</i> , 2012, 65, 751-757.	1.0	78

#	ARTICLE	IF	CITATIONS
91	Prioritizing Phase I Treatment Options Through Preclinical Testing on Personalized Tumorgraft. <i>Journal of Clinical Oncology</i> , 2012, 30, e45-e48.	0.8	79
92	From Node to Pathway Blockade: Lessons Learned From Targeting Mammalian Target of Rapamycin. <i>Journal of Clinical Oncology</i> , 2012, 30, 85-87.	0.8	5
93	Preclinical Activity of the Rational Combination of Selumetinib (AZD6244) in Combination with Vorinostat in KRAS-Mutant Colorectal Cancer Models. <i>Clinical Cancer Research</i> , 2012, 18, 1051-1062.	3.2	41
94	First-Line Cetuximab Plus Capecitabine in Elderly Patients with Advanced Colorectal Cancer: Clinical Outcome and Subgroup Analysis According to KRAS Status from a Spanish TTD Group Study. <i>Oncologist</i> , 2012, 17, 339-345.	1.9	72
95	Convergent structural alterations define SWI/SNF chromatin remodeler as a central tumor suppressive complex in pancreatic cancer. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2012, 109, E252-9.	3.3	192
96	Getting personalized cancer genome analysis into the clinic: the challenges in bioinformatics. <i>Genome Medicine</i> , 2012, 13, 61.	3.6	23
97	The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models. <i>Molecular Cancer Therapeutics</i> , 2012, 11, 1999-2009.	1.9	79
98	Phase I study of the safety, tolerability and pharmacokinetics of PHA-848125AC, a dual tropomyosin receptor kinase A and cyclin-dependent kinase inhibitor, in patients with advanced solid malignancies. <i>Investigational New Drugs</i> , 2012, 30, 2334-2343.	1.2	31
99	Integrated preclinical and clinical development of S-trans, trans-farnesylthiosalicylic acid (FTS,) Tj ETQq1 1 0.784314 µgBT /Overlock 10	1.5	92
100	Biomarker-driven trial in metastatic pancreas cancer: feasibility in a multicenter study of saracatinib, an oral Src inhibitor, in previously treated pancreatic cancer. <i>Cancer Medicine</i> , 2012, 1, 207-217.	1.3	14
101	A Comparison of EGFR Mutation Testing Methods in Lung Carcinoma: Direct Sequencing, Real-time PCR and Immunohistochemistry. <i>PLoS ONE</i> , 2012, 7, e43842.	1.1	88
102	Translational Therapeutic Opportunities in Ductal Adenocarcinoma of the Pancreas. <i>Clinical Cancer Research</i> , 2012, 18, 4249-4256.	3.2	71
103	Stromal Cell-Derived Factor 1 $\pm$ Mediates Resistance to mTOR-Directed Therapy in Pancreatic Cancer. <i>Neoplasia</i> , 2012, 14, 690-IN6.	2.3	44
104	An improved quantitative mass spectrometry analysis of tumor specific mutant proteins at high sensitivity. <i>Proteomics</i> , 2012, 12, 1319-1327.	1.3	22
105	Superior efficacy of co-treatment with dual PI3K/mTOR inhibitor NVP-BEZ235 and pan-histone deacetylase inhibitor against human pancreatic cancer. <i>Oncotarget</i> , 2012, 3, 1416-1427.	0.8	46
106	Exploiting oncogene-induced replicative stress for the selective killing of Myc-driven tumors. <i>Nature Structural and Molecular Biology</i> , 2011, 18, 1331-1335.	3.6	342
107	The inverted pyramid of biomarker-driven trials. <i>Nature Reviews Clinical Oncology</i> , 2011, 8, 562-566.	12.5	17
108	Nodal/Activin Signaling Drives Self-Renewal and Tumorigenicity of Pancreatic Cancer Stem Cells and Provides a Target for Combined Drug Therapy. <i>Cell Stem Cell</i> , 2011, 9, 433-446.	5.2	366

#	ARTICLE	IF	CITATIONS
109	Hybridization for human epidermal growth factor receptor 2 testing in gastric carcinoma: a comparison of fluorescence in-situ hybridization with a novel fully automated dual-colour silver in-situ hybridization method. <i>Histopathology</i> , 2011, 59, 8-17.	1.6	39
110	Early-Onset Colorectal Cancer is an Easy and Effective Tool to Identify Retrospectively Lynch Syndrome. <i>Annals of Surgical Oncology</i> , 2011, 18, 3285-3291.	0.7	21
111	Thymidylate synthase (TYMS) enhancer region genotype-directed phase II trial of oral capecitabine for 2nd line treatment of advanced pancreatic cancer. <i>Investigational New Drugs</i> , 2011, 29, 1057-1065.	1.2	11
112	SEOM clinical guidelines for the treatment of pancreatic cancer. <i>Clinical and Translational Oncology</i> , 2011, 13, 528-535.	1.2	5
113	Inhibition of Ataxia Telangiectasia- and Rad3 -Related Function Abrogates the In Vitro and In Vivo Tumorigenicity of Human Colon Cancer Cells Through Depletion of the CD133+ Tumor-Initiating Cell Fraction. <i>Stem Cells</i> , 2011, 29, 418-429.	1.4	84
114	MK-1775, a Potent Wee1 Inhibitor, Synergizes with Gemcitabine to Achieve Tumor Regressions, Selectively in p53-Deficient Pancreatic Cancer Xenografts. <i>Clinical Cancer Research</i> , 2011, 17, 2799-2806.	3.2	237
115	Tumor Engraftment in Nude Mice and Enrichment in Stroma- Related Gene Pathways Predict Poor Survival and Resistance to Gemcitabine in Patients with Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2011, 17, 5793-5800.	3.2	204
116	Gemcitabine Plus nab-Paclitaxel Is an Active Regimen in Patients With Advanced Pancreatic Cancer: A Phase I/II Trial. <i>Journal of Clinical Oncology</i> , 2011, 29, 4548-4554.	0.8	957
117	Cyclin-dependent kinase inhibitor Dinaciclib (SCH727965) inhibits pancreatic cancer growth and progression in murine xenograft models. <i>Cancer Biology and Therapy</i> , 2011, 12, 598-609.	1.5	103
118	A Pilot Clinical Study of Treatment Guided by Personalized Tumorgrafts in Patients with Advanced Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 1311-1316.	1.9	354
119	Personalizing Cancer Treatment in the Age of Global Genomic Analyses: PALB2 Gene Mutations and the Response to DNA Damaging Agents in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2011, 10, 3-8.	1.9	238
120	SMURF1 Amplification Promotes Invasiveness in Pancreatic Cancer. <i>PLoS ONE</i> , 2011, 6, e23924.	1.1	44
121	Targeted Therapeutics in Cancer Treatment. , 2011, , 403-461.		0
122	Approach to early-onset colorectal cancer: Clinicopathological, familial, molecular and immunohistochemical characteristics. <i>World Journal of Gastroenterology</i> , 2010, 16, 3697.	1.4	39
123	Phase I, pharmacokinetic study of temsirolimus administered orally to patients with advanced cancer. <i>Investigational New Drugs</i> , 2010, 28, 334-342.	1.2	42
124	Quantifying the relative amount of mouse and human DNA in cancer xenografts using species-specific variation in gene length. <i>BioTechniques</i> , 2010, 48, 351-355.	0.8	31
125	Prognostic Significance of Tumorigenic Cells With Mesenchymal Features in Pancreatic Adenocarcinoma. <i>Journal of the National Cancer Institute</i> , 2010, 102, 340-351.	3.0	392
126	A Fine-Needle Aspirate-Based Vulnerability Assay Identifies Polo-Like Kinase 1 as a Mediator of Gemcitabine Resistance in Pancreatic Cancer. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 311-318.	1.9	46



#	ARTICLE	IF	CITATIONS
127	A Combination of DR5 Agonistic Monoclonal Antibody with Gemcitabine Targets Pancreatic Cancer Stem Cells and Results in Long-term Disease Control in Human Pancreatic Cancer Model. <i>Molecular Cancer Therapeutics</i> , 2010, 9, 2582-2592.	1.9	83
128	A Tolerability and Pharmacokinetic Study of Adjuvant Erlotinib and Capecitabine with Concurrent Radiation in Resected Pancreatic Cancer. <i>Translational Oncology</i> , 2010, 3, 373-379.	1.7	18
129	Phase I Trial of Oxaliplatin, Infusional 5-Fluorouracil, and Leucovorin (FOLFOX4) With Erlotinib and Bevacizumab in Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2010, 9, 297-304.	1.0	18
130	Tumor-Initiating Cells Are Rare in Many Human Tumors. <i>Cell Stem Cell</i> , 2010, 7, 279-282.	5.2	205
131	A Commercial Real-Time PCR Kit Provides Greater Sensitivity than Direct Sequencing to Detect KRAS Mutations. <i>Journal of Molecular Diagnostics</i> , 2010, 12, 292-299.	1.2	95
132	Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2010, 362, 1605-1617.	13.9	2,474
133	<i>DPC4</i> Gene Status of the Primary Carcinoma Correlates With Patterns of Failure in Patients With Pancreatic Cancer. <i>Journal of Clinical Oncology</i> , 2009, 27, 1806-1813.	0.8	976
134	Validation of TPX2 as a Potential Therapeutic Target in Pancreatic Cancer Cells. <i>Clinical Cancer Research</i> , 2009, 15, 6519-6528.	3.2	88
135	Efficacy and pharmacodynamic effects of bosutinib (SKI-606), a Src/Abl inhibitor, in freshly generated human pancreas cancer xenografts. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 1484-1493.	1.9	39
136	[ <sup>18</sup> F]Fluorodeoxyglucose Positron Emission Tomography Correlates With Akt Pathway Activity but Is Not Predictive of Clinical Outcome During mTOR Inhibitor Therapy. <i>Journal of Clinical Oncology</i> , 2009, 27, 2697-2704.	0.8	119
137	Phase I and Pharmacokinetic Study of Trabectedin as a 1- or 3-hour Infusion Weekly in Patients with Advanced Solid Malignancies. <i>Clinical Cancer Research</i> , 2009, 15, 3591-3599.	3.2	30
138	A resource for analysis of microRNA expression and function in pancreatic ductal adenocarcinoma cells. <i>Cancer Biology and Therapy</i> , 2009, 8, 2013-2024.	1.5	108
139	The Hedgehog Pathway and Pancreatic Cancer. <i>New England Journal of Medicine</i> , 2009, 361, 2094-2096.	13.9	102
140	Fenugreek: A naturally occurring edible spice as an anticancer agent. <i>Cancer Biology and Therapy</i> , 2009, 8, 272-278.	1.5	83
141	A direct pancreatic cancer xenograft model as a platform for cancer stem cell therapeutic development. <i>Molecular Cancer Therapeutics</i> , 2009, 8, 310-314.	1.9	250
142	Consensus on the treatment of pancreatic cancer in Spain. <i>Clinical and Translational Oncology</i> , 2009, 11, 290-301.	1.2	4
143	Characterizing DNA methylation patterns in pancreatic cancer genome. <i>Molecular Oncology</i> , 2009, 3, 425-438.	2.1	133
144	Combined Targeted Treatment to Eliminate Tumorigenic Cancer Stem Cells in Human Pancreatic Cancer. <i>Gastroenterology</i> , 2009, 137, 1102-1113.	0.6	312

#	ARTICLE	IF	CITATIONS
145	Isolated recurrence of distal adenocarcinoma of the extrahepatic bile duct on a draining sinus scar after curative resection: Case Report and review of the literature. <i>World Journal of Surgical Oncology</i> , 2009, 7, 96.	0.8	3
146	Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2009, 15, 4138-4146.	3.2	79
147	Mycophenolate mofetil: An update. <i>Drugs of Today</i> , 2009, 45, 521.	0.7	105
148	Phase I and pharmacokinetic study of UCN-01 in combination with irinotecan in patients with solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 61, 423-433.	1.1	35
149	Phase I trial of weekly trabectedin (ET-743) and gemcitabine in patients with advanced solid tumors. <i>Cancer Chemotherapy and Pharmacology</i> , 2008, 63, 181-188.	1.1	31
150	Determination of salirasib (S-trans,trans-farnesylthiosalicylic acid) in human plasma using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2008, 869, 142-145.	1.2	4
151	Methylation alterations are not a major cause of PTTG1 missregulation. <i>BMC Cancer</i> , 2008, 8, 110.	1.1	4
152	Novel Microtubule-Interacting Phenoxy Pyridine and Phenyl Sulfanyl Pyridine Analogues for Cancer Therapy. <i>Journal of Medicinal Chemistry</i> , 2008, 51, 5953-5957.	2.9	28
153	Core Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses. <i>Science</i> , 2008, 321, 1801-1806.	6.0	3,755
154	New scaffolds for the design of selective estrogen receptor modulators. <i>Organic and Biomolecular Chemistry</i> , 2008, 6, 3486.	1.5	24
155	Activated Epidermal Growth Factor Receptor as a Novel Target in Pancreatic Cancer Therapy. <i>Journal of Proteome Research</i> , 2008, 7, 4651-4658.	1.8	42
156	Phase I Study of ON 01910.Na, a Novel Modulator of the Polo-Like Kinase 1 Pathway, in Adult Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2008, 26, 5504-5510.	0.8	104
157	Coordinated Epidermal Growth Factor Receptor Pathway Gene Overexpression Predicts Epidermal Growth Factor Receptor Inhibitor Sensitivity in Pancreatic Cancer. <i>Cancer Research</i> , 2008, 68, 2841-2849.	0.4	89
158	Antitumor activity and molecular effects of the novel heat shock protein 90 inhibitor, IPI-504, in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2008, 7, 3275-3284.	1.9	77
159	Genome-wide profiling at methylated promoters in pancreatic adenocarcinoma. <i>Cancer Biology and Therapy</i> , 2008, 7, 1146-1156.	1.5	165
160	A Phase I Study of EKB-569 in Combination with Capecitabine in Patients with Advanced Colorectal Cancer. <i>Clinical Cancer Research</i> , 2008, 14, 5602-5609.	3.2	28
161	Pharmacodynamic-Guided Modified Continuous Reassessment Method-Based, Dose-Finding Study of Rapamycin in Adult Patients With Solid Tumors. <i>Journal of Clinical Oncology</i> , 2008, 26, 4172-4179.	0.8	63
162	Analysis of Fluorouracil-Based Adjuvant Chemotherapy and Radiation After Pancreaticoduodenectomy for Ductal Adenocarcinoma of the Pancreas: Results of a Large, Prospectively Collected Database at the Johns Hopkins Hospital. <i>Journal of Clinical Oncology</i> , 2008, 26, 3503-3510.	0.8	343

#	ARTICLE	IF	CITATIONS
163	Clinical Development of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitors: What Lessons Have We Learned?. <i>Advances in Experimental Medicine and Biology</i> , 2008, 610, 128-143.	0.8	4
164	Optimizing the development of targeted agents in pancreatic cancer: tumor fine-needle aspiration biopsy as a platform for novel prospective ex vivo drug sensitivity assays. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 515-523.	1.9	26
165	Association of variant ABCG2 and the pharmacokinetics of epidermal growth factor receptor tyrosine kinase inhibitors in cancer patients. <i>Cancer Biology and Therapy</i> , 2007, 6, 432-438.	1.5	177
166	Differential Metabolism of Gefitinib and Erlotinib by Human Cytochrome P450 Enzymes. <i>Clinical Cancer Research</i> , 2007, 13, 3731-3737.	3.2	283
167	Development of two novel benzoylphenylurea sulfur analogues and evidence that the microtubule-associated protein tau is predictive of their activity in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1509-1516.	1.9	29
168	Panitumumab, a Monoclonal Anti-EGFR Antibody in Colorectal Cancer: Another One or the One?: Table 1.. <i>Clinical Cancer Research</i> , 2007, 13, 4664-4666.	3.2	44
169	Dual mitogen-activated protein kinase and epidermal growth factor receptor inhibition in biliary and pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2007, 6, 1079-1088.	1.9	30
170	A Randomized, Phase II Trial of Two Dose Levels of Temozolomide (CC-779) in Patients with Extensive-Stage Small-Cell Lung Cancer Who Have Responding or Stable Disease after Induction Chemotherapy: A Trial of the Eastern Cooperative Oncology Group (E1500). <i>Journal of Thoracic Oncology</i> , 2007, 2, 1036-1041.	0.5	145
171	Expression of Epiregulin and Amphiregulin and K-ras Mutation Status Predict Disease Control in Metastatic Colorectal Cancer Patients Treated With Cetuximab. <i>Journal of Clinical Oncology</i> , 2007, 25, 3230-3237.	0.8	1,109
172	Targeted Therapeutics in Cancer Treatment. , 2007, , 117-148.		0
173	A rapid and sensitive method for determination of sorafenib in human plasma using a liquid chromatography/tandem mass spectrometry assay. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 846, 1-7.	1.2	46
174	Validation and implementation of a liquid chromatography/tandem mass spectrometry assay to quantitate ON 01910.Na, a mitotic progression modulator, in human plasma. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2007, 856, 198-204.	1.2	11
175	Analysis of biologic surrogate markers from a Children's Oncology Group Phase I trial of gefitinib in pediatric patients with solid tumors. <i>Pediatric Blood and Cancer</i> , 2007, 49, 352-357.	0.8	12
176	Exploiting novel molecular targets in gastrointestinal cancers. <i>World Journal of Gastroenterology</i> , 2007, 13, 5845.	1.4	16
177	Epidermal Growth Factor Receptor Inhibition in Non-Small Cell Lung Cancer. <i>Translational Medicine Series</i> , 2007, , 81-96.	0.0	0
178	Benzoylphenylurea Sulfur Analogues with Potent Antitumor Activity. <i>Journal of Medicinal Chemistry</i> , 2006, 49, 2357-2360.	2.9	41
179	Multitargeted therapy: Can promiscuity be praised in an era of political correctness?. <i>Critical Reviews in Oncology/Hematology</i> , 2006, 59, 150-158.	2.0	30
180	Binding of gefitinib, an inhibitor of epidermal growth factor receptor-tyrosine kinase, to plasma proteins and blood cells: in vitro and in cancer patients. <i>Investigational New Drugs</i> , 2006, 24, 291-297.	1.2	70

#	ARTICLE	IF	CITATIONS
181	Pharmacogenomics of epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2006, 1766, 217-229.	3.3	32
182	C-fos Assessment as a Marker of Anti-EGFR Epidermal Growth Factor Receptor Effect. <i>Cancer Research</i> , 2006, 66, 2385-2390.	0.4	36
183	Cetuximab in squamous cell carcinoma of the head and neck. <i>Future Oncology</i> , 2006, 2, 449-457.	1.1	3
184	An In vivo Platform for Translational Drug Development in Pancreatic Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 4652-4661.	3.2	407
185	A Phase I Clinical and Pharmacokinetic Study of Oral CI-1033 in Combination with Docetaxel in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 4274-4282.	3.2	31
186	Phase I, Pharmacokinetic, and Biological Study of Erlotinib in Combination with Paclitaxel and Carboplatin in Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 7406-7413.	3.2	20
187	CYP3A Phenotyping Approach to Predict Systemic Exposure to EGFR Tyrosine Kinase Inhibitors. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1714-1723.	3.0	102
188	Phase I Study of EKB-569, an Irreversible Inhibitor of the Epidermal Growth Factor Receptor, in Patients With Advanced Solid Tumors. <i>Journal of Clinical Oncology</i> , 2006, 24, 2252-2260.	0.8	138
189	Assessment of gefitinib- and CI-1040-mediated changes in epidermal growth factor receptor signaling in HuCCT-1 human cholangiocarcinoma by serial fine needle aspiration. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 1895-1903.	1.9	14
190	A Phase I and Pharmacokinetic Study of Temsirolimus (CCI-779) Administered Intravenously Daily for 5 Days Every 2 Weeks to Patients with Advanced Cancer. <i>Clinical Cancer Research</i> , 2006, 12, 5755-5763.	3.2	213
191	Pharmacogenetics of ABCG2 and Adverse Reactions to Gefitinib. <i>Journal of the National Cancer Institute</i> , 2006, 98, 1739-1742.	3.0	232
192	Immunohistochemical and Genetic Evaluation of Deoxycytidine Kinase in Pancreatic Cancer: Relationship to Molecular Mechanisms of Gemcitabine Resistance and Survival. <i>Clinical Cancer Research</i> , 2006, 12, 2492-2497.	3.2	141
193	Assessment of celecoxib pharmacodynamics in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 3240-3247.	1.9	30
194	Molecular biomarkers: their increasing role in the diagnosis, characterization, and therapy guidance in pancreatic cancer. <i>Molecular Cancer Therapeutics</i> , 2006, 5, 787-796.	1.9	83
195	Population Pharmacokinetics of Troxacitabine, a Novel Dioxolane Nucleoside Analogue. <i>Clinical Cancer Research</i> , 2006, 12, 2158-2165.	3.2	12
196	Pharmacokinetics of Cetuximab After Administration of Escalating Single Dosing and Weekly Fixed Dosing in Patients with Solid Tumors. <i>Clinical Cancer Research</i> , 2006, 12, 6517-6522.	3.2	95
197	Epidermal Growth Factor Receptor Dynamics Influences Response to Epidermal Growth Factor Receptor Targeted Agents. <i>Cancer Research</i> , 2005, 65, 3003-3010.	0.4	105
198	Specific method for determination of gefitinib in human plasma, mouse plasma and tissues using high performance liquid chromatography coupled to tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2005, 819, 73-80.	1.2	61

#	ARTICLE	IF	CITATIONS
199	Design, synthesis and biological evaluation of novel riccardiphenol analogs. <i>Bioorganic and Medicinal Chemistry</i> , 2005, 13, 2873-2880.	1.4	19
200	Current Status of Mammalian Target of Rapamycin Inhibitors in Lung Cancer. <i>Clinical Lung Cancer</i> , 2005, 7, S13-S18.	1.1	15
201	Blockade of epidermal growth factor receptor (EGFR) activity. <i>Critical Reviews in Oncology/Hematology</i> , 2005, 53, 179-192.	2.0	23
202	Treating Cancer by Blocking Cell Signals. <i>Journal of Clinical Oncology</i> , 2005, 23, 5279-5280.	0.8	15
203	In vitro and In vivo Clinical Pharmacology of Dimethyl Benzoylphenylurea, a Novel Oral Tubulin-Interactive Agent. <i>Clinical Cancer Research</i> , 2005, 11, 8503-8511.	3.2	10
204	Promises and pitfalls in the prediction of antiepidermal growth factor receptor activity. <i>Expert Review of Anticancer Therapy</i> , 2005, 5, 727-735.	1.1	2
205	Assessment of epidermal growth factor receptor (EGFR) signaling in paired colorectal cancer and normal colon tissue samples using computer-aided immunohistochemical analysis. <i>Cancer Biology and Therapy</i> , 2005, 4, 1381-1386.	1.5	35
206	Immortalizing the complexity of cancer metastasis: Genetic features of lethal metastatic pancreatic cancer obtained from rapid autopsy. <i>Cancer Biology and Therapy</i> , 2005, 4, 548-554.	1.5	132
207	Phase II Trial of Temsirolimus (CCI-779) in Recurrent Glioblastoma Multiforme: A North Central Cancer Treatment Group Study. <i>Journal of Clinical Oncology</i> , 2005, 23, 5294-5304.	0.8	688
208	Homozygous deletions of methylthioadenosine phosphorylase in human biliary tract cancers. <i>Molecular Cancer Therapeutics</i> , 2005, 4, 1860-1866.	1.9	31
209	Intracellular Signal Transduction Pathway Proteins As Targets for Cancer Therapy. <i>Journal of Clinical Oncology</i> , 2005, 23, 5386-5403.	0.8	191
210	Randomized Phase II Study of Multiple Dose Levels of CCI-779, a Novel Mammalian Target of Rapamycin Kinase Inhibitor, in Patients With Advanced Refractory Renal Cell Carcinoma. <i>Journal of Clinical Oncology</i> , 2004, 22, 909-918.	0.8	948
211	New Target, New Drug, Old Paradigm. <i>Journal of Clinical Oncology</i> , 2004, 22, 2270-2272.	0.8	19
212	Phase I Trial of Irinotecan, Infusional 5-Fluorouracil, and Leucovorin (FOLFIRI) with Erlotinib (OSI-774). <i>Clinical Cancer Research</i> , 2004, 10, 6522-6527.	3.2	81
213	A Phase I and Pharmacokinetic Study of Col-3 (Metastat), an Oral Tetracycline Derivative with Potent Matrix Metalloproteinase and Antitumor Properties. <i>Clinical Cancer Research</i> , 2004, 10, 6512-6521.	3.2	60
214	The V599E BRAF mutation is uncommon in biliary tract cancers. <i>Modern Pathology</i> , 2004, 17, 1386-1391.	2.9	40
215	Predictors of Sensitivity and Resistance to Epidermal Growth Factor Receptor Inhibitors. <i>Clinical Lung Cancer</i> , 2004, 6, S30-S34.	1.1	15
216	Mac-2-binding protein is a diagnostic marker for biliary tract carcinoma. <i>Cancer</i> , 2004, 101, 1609-1615.	2.0	95

#	ARTICLE	IF	CITATIONS
217	Synthesis and antitumor evaluation of benzoylphenylurea analogs. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2004, 14, 2213-2216.	1.0	25
218	Multicenter Phase II Study of Erlotinib, an Oral Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Recurrent or Metastatic Squamous Cell Cancer of the Head and Neck. <i>Journal of Clinical Oncology</i> , 2004, 22, 77-85.	0.8	753
219	An Epidermal Growth Factor Receptor Intron 1 Polymorphism Mediates Response to Epidermal Growth Factor Receptor Inhibitors. <i>Cancer Research</i> , 2004, 64, 9139-9143.	0.4	242
220	Epidermal Growth Factor Receptor as a Therapeutic Target for the Treatment of Colorectal Cancer. <i>Clinical Colorectal Cancer</i> , 2004, 4, 51-62.	1.0	15
221	Inhibition of mTOR Activity Restores Tamoxifen Response in Breast Cancer Cells with Aberrant Akt Activity. <i>Clinical Cancer Research</i> , 2004, 10, 8059-8067.	3.2	376
222	New targets for therapy in breast cancer: Mammalian target of rapamycin (mTOR) antagonists. <i>Breast Cancer Research</i> , 2004, 6, 219-24.	2.2	83
223	Pharmacokinetics and pharmacodynamics: Maximizing the clinical potential of Erlotinib (Tarceva). <i>Seminars in Oncology</i> , 2003, 30, 25-33.	0.8	81
224	Specific method for determination of OSI-774 and its metabolite OSI-420 in human plasma by using liquid chromatography-tandem mass spectrometry. <i>Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences</i> , 2003, 793, 413-420.	1.2	61
225	Identification of Novel Cellular Targets in Biliary Tract Cancers Using Global Gene Expression Technology. <i>American Journal of Pathology</i> , 2003, 163, 217-229.	1.9	117
226	Developing Inhibitors of the Epidermal Growth Factor Receptor for Cancer Treatment. <i>Journal of the National Cancer Institute</i> , 2003, 95, 851-867.	3.0	349
227	Recent advances in the pharmacological treatment of colorectal cancer. <i>Expert Opinion on Investigational Drugs</i> , 2003, 12, 423-434.	1.9	8
228	Development of The Epidermal Growth Factor Receptor Inhibitor Tarcevatm(Osi-774). <i>Advances in Experimental Medicine and Biology</i> , 2003, 532, 235-246.	0.8	50
229	Development of the epidermal growth factor receptor inhibitor OSI-774. <i>Seminars in Oncology</i> , 2003, 30, 23-31.	0.8	143
230	An Introduction to Pancreatic Adenocarcinoma Genetics, Pathology and Therapy. <i>Cancer Biology and Therapy</i> , 2002, 1, 607-613.	1.5	44
231	Development of matrix metalloproteinase inhibitors in cancer therapy. <i>Hematology/Oncology Clinics of North America</i> , 2002, 16, 1189-1227.	0.9	21
232	Promising Developments in Targeted Therapies for non-small-Cell Lung Cancer. <i>Clinical Lung Cancer</i> , 2002, 4, 111-123.	1.1	3
233	Angiogenesis inhibitors in clinical development for lung cancer. <i>Seminars in Oncology</i> , 2002, 29, 66-77.	0.8	48
234	The epidermal growth factor receptor: A new target for anticancer therapy. <i>Current Problems in Cancer</i> , 2002, 26, 114-164.	1.0	54

#	ARTICLE	IF	CITATIONS
235	Pancreatic cancer. <i>Current Problems in Cancer</i> , 2002, 26, 176-275.	1.0	268
236	Development of Matrix Metalloproteinase Inhibitors in Cancer Therapy. <i>Journal of the National Cancer Institute</i> , 2001, 93, 178-193.	3.0	732
237	Phase I and Pharmacokinetic Study of BMS-184476, a Taxane With Greater Potency and Solubility Than Paclitaxel. <i>Journal of Clinical Oncology</i> , 2001, 19, 2493-2503.	0.8	34
238	Phase I and Pharmacologic Study of OSI-774, an Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor, in Patients With Advanced Solid Malignancies. <i>Journal of Clinical Oncology</i> , 2001, 19, 3267-3279.	0.8	981
239	Phase I and Pharmacokinetic Study of NSC 655649, a Rebeccamycin Analog With Topoisomerase Inhibitory Properties. <i>Journal of Clinical Oncology</i> , 2001, 19, 2937-2947.	0.8	38
240	The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. <i>Oncogene</i> , 2000, 19, 6680-6686.	2.6	561
241	Phase I and Pharmacologic Study of the Specific Matrix Metalloproteinase Inhibitor BAY 12-9566 on a Protracted Oral Daily Dosing Schedule in Patients With Solid Malignancies. <i>Journal of Clinical Oncology</i> , 2000, 18, 178-178.	0.8	76